An Educational Resource by
Women's Cancer Initiative - Tata Memorial Hospital
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: A real-world outcomes study Annals of Oncology
Molecular classication of hormone receptor-positive HER2-negative breast cancer
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial
Speaker : Dr. Bhawna Sirohi
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Speaker : Dr. Shruti Kate
Phase III study of adjuvant ado trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE nal IDFS and updated OS analysis
HER2CLIMB-02: Randomized, double blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer
Speaker : Dr. Manuprasad Avaronnan
A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with metastatic HER2 positive breast cancer (JCOG1607 HERB TEA study)
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as rst line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
Speaker : Dr. Prabhat Bhargava
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA nal ecacy data
A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
Speaker : Dr. Amit Kumar
Do tumor inltrating lymphocytes (TILs) predict benets from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials
HER2 amplication level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
Speaker : Dr. Priya Tiwari
ADCs in the treatment of breast cancer – Present status and future developments. Is breast cancer leading the way
Speaker : Dr. Hope Rugo
Panel discussion on key abstracts in HER2+ve Breast Cancer
Moderator : Dr. Nitesh Rohatgi
The era of precision oncology in breast cancer: Novel Targets and treatments
Speaker : Dr. Giuseppe Curigliano
Molecular Tumor Board in Breast Cancer
Moderator : Dr. B K Smruti
Digital Oncology: Progress and Future Outlook
Speaker : Dr. Nikesh R. Shah